HK Stock Market Move | NANHUA FUTURES (02691) rose over 4% in the afternoon, with first-half results showing high growth; overseas platforms contributed over 90% of profits.
NANHUA FUTURES (02691) rose over 4% in the afternoon. As of press time, it was up 4.10% at HK$6.86, with a turnover of HK$21.9518 million.
NANHUA FUTURES (02691) rose over 4% in the afternoon. As of press time, it was up 4.10% at HK$6.86, with a turnover of HK$21.9518 million.
On the news front, Nanhua Futures' interim results show that first-half net profit attributable to shareholders was RMB 388 million, already reaching 80% of last year's full-year figure. Among this, core overseas subsidiary Heng Hua International achieved operating revenue of RMB 522 million in 1H26, with net profit reaching RMB 361 million, up 63.5% year-on-year, accounting for over 90% of the company's net profit, as its position as a core profit growth engine continues to strengthen.
Huachuang Securities pointed out that Nanhua Futures is a leader among Chinese-funded futures firms expanding overseas to build a global proprietary clearing network, possessing both a compliance moat and capital/information security barriers. With the surge in risk management demand from Chinese enterprises going global, the strengthening of capital resources across its A+H dual-platform, and the advancement of its H-share buyback plan, the company is entering a strategic window of opportunity for value revaluation as a global clearing house.
Related Articles

Hefei Lifeon Pharmaceutical (003020.SZ): Marketing application for dexmethylphenidate hydrochloride API approved

ZhuZhou QianJin Pharmaceutical (600479.SH): Ferrous Succinate Tablets and Escitalopram Oxalate Tablets Obtain Drug Registration Certificates

Kexing Biopharm (688136.SH): GB20 Injection Receives Drug Clinical Trial Approval Notice
Hefei Lifeon Pharmaceutical (003020.SZ): Marketing application for dexmethylphenidate hydrochloride API approved

ZhuZhou QianJin Pharmaceutical (600479.SH): Ferrous Succinate Tablets and Escitalopram Oxalate Tablets Obtain Drug Registration Certificates

Kexing Biopharm (688136.SH): GB20 Injection Receives Drug Clinical Trial Approval Notice

RECOMMEND





